Abstract
Background The MitraClip device (Abbott), an FDA-approved transcatheter apparatus, is employed for the management of mitral regurgitation (MR) among patients deemed at high risk for surgical interventions. We analyzed reports in the FDA MAUDE database to evaluate the safety trend in fatal complications associated with MitraClip implantation in the last decade.
Methods We searched the publicly accessible Manufacturer and User Facility Device Experience (MAUDE) database for reports of deaths and injuries associated with MitraClip implantation from October 2013 to September 2023. Duplicate reports were excluded. The Cochran-Armitage test was used to analyze the trend in proportion of fatal events.
Results In the 10 year period after FDA approval, a total of 927 death reports and 9211 injury reports were recorded by the MAUDE database. 592 death reports were included for analysis after excluding duplicates and reports from other sources. The most frequently reported complications were MR (26.69%), tissue damage (24.16%) and hypotension (22.13% ). The most common device-related problems were incomplete coaptation (14.70%), difficult to remove (6.42%), and failure to adhere or bond/positioning failure(4.90%). Most deaths (76.94%) occurred within one year of implantation. The proportion of reported fatal events showed a significant declining trend from 15.9% in 2014-2015 to 3.5% in 2020-2021 (p<0.0001).
Conclusions Analysis of the MAUDE database suggests a decline in reported fatal events associated with MitraClip implantation over time, which may reflect increasing experience with the device. However, passive reporting has limitations including underreporting and incomplete data. Further studies are needed to better characterize the safety profile and complication rates of MitraClip implantation in real-world practice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The authors report no financial relationships or conflicts of interest regarding the content herein.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Supplemented data from September 2022 to October 2023
Data Availability
All data produced are available online at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM
